HC Wainwright reaffirmed their neutral rating on shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $2.00 target price on the stock.
Lyra Therapeutics Trading Down 1.7 %
NASDAQ:LYRA opened at $0.17 on Friday. Lyra Therapeutics has a 12 month low of $0.16 and a 12 month high of $6.79. The stock has a market cap of $11.26 million, a price-to-earnings ratio of -0.12 and a beta of -0.18. The company has a 50-day moving average price of $0.19 and a 200-day moving average price of $0.22.
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Lyra Therapeutics had a negative net margin of 6,635.76% and a negative return on equity of 125.07%. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. During the same period last year, the business earned ($1.26) earnings per share. Equities analysts forecast that Lyra Therapeutics will post -0.93 EPS for the current fiscal year.
Institutional Inflows and Outflows
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Further Reading
- Five stocks we like better than Lyra Therapeutics
- How to Start Investing in Real Estate
- How to Build the Ultimate Everything ETF Portfolio
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.